natgillin/translations-raw huggingface dataset:
The orodispersible film according to claim 8, wherein the glycerol is at a concentration from 5 to 10% w/w; the polysorbate 80 is at a concentration from 4 to 6% w/w; and the sweetener is at a concentration from 4 to 7% w/w of the total weight of the film. 
Orodisperzibilan film prema zahtjevu 8, naznačen time da je glicerol koncentracije od 5 do 10% m/m; polisorbat 80 je koncentracije od 4 do 6% m/m, i zaslađivač je koncentracije od 4 do 7% m/m ukupne težine filma.
Chemically modified heparin having an antifactor IIa activity and an antifactor Xa activity, wherein the antifactor IIa activity is up to 10 IU/mg and the antifactor Xa activity of up to 10 IU/mg, wherein the chemically modified heparin has a weight average molecular weight from about 6.5 to about 9.5 kDa, wherein the polysaccharide chains: 
HR P20180726 T1 PATENTNI ZAHTJEVI Kemijski modificiran heparin za upotrebu u liječenju bolesti srpastih stanica, pri čemu kemijski modificiran heparin ima aktivnost antifaktora Ila manju od 10 IU/mg, aktivnost antifaktora Xa do 10 IU/mg i prosječnu molekularnu masu od 6,5 do 9,5 kDa, naznačen time da polisaharidni lanci:
A method of detecting, diagnosing and/or screening for or monitoring the progression of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer or of monitoring the effect of an anti-colorectal cancer, anti-kidney cancer, anti-liver cancer, anti-lung cancer, anti- lymphoid leukaemia (particularly chronic lymphocytic leukaemia), anti-ovarian cancer or anti-pancreatic cancer drug or therapy in a subject which comprises detecting the presence or level of antibodies capable of immunospecific binding to Lymphocyte antigen 75, or one or more epitope-containing fragments thereof or which comprises detecting a change in the level thereof in said subject; 
In vitro postupak za detektiranje, dijagnosticiranje i/ili skrining za ili nadgledanje napredovanja raka pankreasa ili nadgledanja djelovanja lijeka protiv raka pankreasa ili terapije kod subjekta koji obuhvaća detektiranje prisutnosti ili razine antitijela koja su sposobna za imunospecifično vezivanje na limfocitni antigen 75, ili jedan ili više epitopa koji sadrže njegove fragmente ili koji obuhvaćaju detektiranje promjene u njihovoj razini kod spomenutog subjekta;
An installation according to claim 1, wherein the installation comprises windmills in pairs. 
Instalacija prema zahtjevu 1, naznačena time što instalacija (1) sadrži vjetrenjače (4) u parovima.
The injector of any one of the preceding claims, wherein the actuator is adapted to delay movement of the container needle from the storage state to the delivery state after an input is received. 
Ubrizgač prema bilo kojem od prethodnih zahtjeva, naznačen time, što je pokretač (456) prilagođen da odgodi kretanje igle spremnika (550, 702, 772) 1z pasivnog stanja u stanje za isporuku nakon primanja unosa.
Device as claimed in claim 1 wherein said air bubble separation device is produced by means of a chamber with two special membranes one of which permits, at the working pressures, passage of the liquid along the fluidic line but separation of the bubbles, while the other permits outflow of the air accumulated in the chamber but not that of the perfusion liquid. 
Uređaj prema patentnim zahtjevima 2 - 11, naznačen time što je navedeni uređaj (33) za separaciju mjehurića zraka proizveden pomoću komore sa dvije posebne opne, od kojih jedna dopušta, na radnom tlaku, prolaz tekućine duž fluidne linije, ali odvajanje mjehurića, dok druga dopušta isticanje zraka akumuliranog u komori, ali ne i onog iz perfuzione tekućine.
a peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence of SEQ ID NO: 288, in which 1 or 2 amino acids are substituted, wherein said peptide induces a cytotoxic T cell specific to an HLA-A2 positive cell expressing URLC10; 
Peptid od manje od 15 aminokiselina koja može inducirati citotoksične T-stanice, gdje navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO: 30, 19, 22, 34, te 358, u kojem su 1 ili 2 aminokiseline zamijenjene, izbačene ili dodane, naznačen time što navedeni peptid inducira citotoksične T-limfocite specifične za stanicu koja eksprimira CDH3.
a poly(A) sequence or a polyadenylation signal, for use for increasing the expression of said protein encoded by the coding region as defined by (a) in the treatment of cancer diseases, infectious diseases, autoimmune diseases, allergies or allergic diseases, monogenetic diseases, genetic diseases, cardiovascular diseases, neuronal diseases, diseases of the respiratory system, diseases of the digestive system, diseases of the skin, musculoskeletal disorders, disorders of the connective tissue, immune deficiencies, endocrine, nutritional and metabolic diseases, eye diseases or ear diseases. 
C) -poli(A) sekvencu ili poliadenilacijski signal, naznačena time da je za uporabu za povećanje ekspresije navedenog proteina koji kodira kodirajuće područje kako je definirano u (a) za liječenje kanceroznih bolesti, zaraznih bolesti, autoimunih bolesti, alergija ili alergijskih bolesti, monogenetskih bolesti, genetskih bolesti, kardiovaskularnih bolesti, neuronskih bolesti, bolesti dišnog sustava, bolesti probavnog sustava, kožnih bolesti, muskuloskeletalnih poremećaja, poremećaja vezivnog tkiva, imunodeficijencija, endokrinih, prehrambenih i metaboličkih bolesti, očnih bolesti ili bolesti uha.
The slits of the collar 25 provide resiliency to the collar 25, and causes the collar 25 to flex outwards, when the piercer 11 is forced towards the container 2 to pierce the closure 22 at a weak section as shown in FIG. 2 c. 
Zarezi u prstenu 25 osiguravaju elastičnost prstena 25, i uzrokuju da se prsten 25 savije prema van kad se bušilo 11 prisili da ide prema spremniku 2 i da probije poklopac 22 na slabijem dijelu, kao što je prikazano na slici 2c.
In an another embodiment, A is an immunogenic fragment of UspA2, wherein UspA2 is at least 95% identical to SEQ ID NO: 1. 
(formula 1) naznačen time što: A je imunogeni fragment UspA2 iz bakterije Moraxella catarrhalis koji je najmanje 90% istovjetan sa SEQ ID
The process of claim 9, wherein when in step a) a suspension is formed, the solvent used does not contain water and the stabilizing agent is in the form of particles having a mean particle size of 1 - 9 µm. 
Postupak prema zahtjevu 9, naznačen time da kada u koraku a) nastaje suspenzija, korišteno otapalo ne sadrži vodu 1 sredstvo za stabiliziranje je u obliku čestica koje imaju srednju veličinu čestica od 1 - 9 um.
In one embodiment, R3 is selected from the group consisting of hydrogen, 
Spoj prema Zahtjevu 19, naznačen time, da R; je odabran iz skupine koja sadrži
Figure 3: Inhibition of LPS-induced (systemic) TNFa release in rats by a combination of COMPOUND A and ATORVASTATIN hemi-calcium sesqui-hydrate Pharmaceutical composition comprising a pharmaceutical formulation including an amount of a PDE4 inhibitor or a pharmaceutically acceptable salt thereof, an amount of a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, wherein the first amount and the second amount together comprise an effective amount for the preventive or curative treatment of an inflammatory pulmonary disease, and at least one pharmaceutically acceptable auxiliary. 
Farmaceutski sastav, naznačen time, da obuhvaća farmaceutsku formulaciju koja uključuje jednu količinu PDE4- inhibitora, jednu količinu inhibitora reduktaze HMG-CoA 1 barem jedno farmaceutski prihvatljivo pomoćno sredstvo, dok je PDEA-inhibitor odabran iz skupine koja sadrži ROFLUMILAST, farmaceutski prihvatljivu sol ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljivu sol ROFLUMILAST-N-oksida, gdje inhibitor reduktaze HMG-CoA je ATORVASTATIN ili njegova farmaceutski prihvatljiva sol, pri čemu prva količina 1 druga količina zajedno sastavljaju djelotvornu količinu za preventivno i kurativno liječenje upalne bolesti pluća.
The pharmaceutical composition of claim 4, wherein the pharmaceutically acceptable carrier is silicified microcrystalline cellulose. 
Farmaceutski pripravak prema patentnim zahtjevima 1 ili 2, naznačen time što je farmaceutski prihvatljiv nosač silicificirana mikrokristalna celuloza.
a second reservoir unit (4) for storing a second reactant for preparation of chlorine dioxide. The apparatus as claimed in claim 1, wherein the first reactant in the first reservoir unit (8) 
Uređaj prema zahtjevu 1, naznačen time što je prvi reaktant u prvoj jedinici spremnika (8) odabran iz skupine koja se sastoji od peroksodisulfata i klorita.
The method of claim 11, wherein said clostridial neurotoxin is of serotype A, and wherein said one or more receptors are taken from the list of: SV2, a ganglioside receptor, and a biologically active derivative of SV2 or a ganglioside receptor. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time, da je rečeni klostridijski neurotoksin od serotipa A te pri čemu je rečeni jedan ili više receptora izabrano sa popisa: SV2, gangliozidni receptor i biološki aktivan derivat SV2 ili gangliozidni receptor.
or a pharmaceutically acceptable salt or solvate thereof, wherein: Z is 
OOH ili njegova farmaceutski prihvatljiva sol ili solvat, naznačeno time, da:
Coating composition according to any of claims 1 to 4, characterised in that said SMGCC has a d 98 of less than or equal to 1 µm, preferably of less than or equal to 0.8 µm, more preferably of less than or equal to 0.6 µm, even more preferably of less than or equal to 0.4 µm, and, e.g. is 0.3 µm. 
Sastav za oblaganje u skladu s bilo kojim od patentnih zahtjeva 1 do4, karakteriziran na način da navedeni SNGCC ima d98 manji ili jednak 1 µm, poželjno manji ili jednak 0.8 µm, poželjnije manji ili jednak 0.6 µm, čak još poželjnije manji ili jednak 0.4 µm.
conversion of 4, particularly under conditions of a Sharpless oxidation, to create compound F; 
prevođenje spoja 4 ili 4*, naročito pod uvjetima oksidacije Sharplessove, kako bi se dobio spoj F ili spoj F*;
The water carbonator according to claim 2, additionally comprising ring gaskets (18, 3) sealing said tube (1) and respective closure elements (2, 4). 
Aparat za obogaćivanje vode karbonatnom kiselinom iz zahtjeva 1, naznačen time da elementi za zatvaranje (2, 4) imaju vanjski utor u kojem se nalazi brtva (18, 3).
the concentration of the recovered autoactivating proelastase protein in the solution is less than 10 mg/ml, less than 5 mg/ml, less than 2 mg/ml, less than 1 mg/ml, less than 0.5 mg/ml, less than 0.25 mg/ml and/or at least 0.1mg/ml or at least 0.2 mg/ml; and/or 
(iii) koncentracija oporavljenog autoaktivacijskog proteina proelastaze u otopini je manja od 10 mg/ml, manja od 5 mg/ml, manja od 2 mg/ml, manja od 1 mg/ml, manja od 0,5 mg/ml, manja od 0,25 mg/ml i/ili najmanja od 0,1 mg/ml ili najmanja od 0,2 mg/ml; i/ili
a mixture of about 2,83 weight percent PEG-40 stearate and about 0,98 weight percent polysorbate 80, 
mješavinu PEG-40 stearata i polisorbata 80 kao emulgator,
Use according to one of the claims 8, 9 or 10 wherein the patient is an individual with insufficient glycemic control despite monotherapy with a SGLT2 inhibitor, in particular a glucopyranosyl-substituted benzene derivative of the formula (I) according to claim 1 or 2. 
18. Farmaceutski sastav za uporabu prema zahtjevu 11, 12 ili 13, naznačen time, da je pacijent pojedinac s nedovoljnom glikemijskom kontrolom usprkos monoterapiji sa SGLT2-inhibitorom, posebno s derivatom benzena 10
The pharmaceutical composition of claim 10 or claim 11, wherein the additional therapeutic agents are each independently selected from the group consisting of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, and other drugs for treating HIV. 
Farmaceutski pripravak prema zahtjevu 10 ili zahtjevu 11, naznačen time da je svako dodatno terapeutsko sredstvo neovisno odabrano iz skupine koja sadrži inhibitore HIV proteaze, nenukleozidne inhibitore HIV reverzne transkriptaze, nukleozidne inhibitore HIV reverzne transkriptaze, nukleotidne inhibitore HIV reverzne transkriptaze, i druge lijekove za liječenje HIV-a.
is selected from hydrogen, halo, difluoromethyl, trifluoromethyl and methyl; 
R* je odabran od sljedećih: vodik, halogen, difluorometil, trifluorometil i metil;
The method of any of the above items, wherein said dilution rate and said cell density are maintained for at least 80 % of the time the cells are cultured in said cell culture system. 
Postupak prema bilo kojem od gornjih zahtjeva, pri čemu su navedeni stupanj razrjeđenja i navedena gustoća stanica održavani barem 80 % vremena kultiviranja stanica u navedenom sustavu stanične kulture.
Welded plastic container bag according to claim 8, wherein the support welds comprise a significantly weaker bond than the corner welds. 
Zavarena plastična vrećica za spremnik u skladu s patentnim zahtjevom 4, naznačena time što potporni dijelovi za zavarivanje značajno sadrže slabiju vezu od kutnih dijelova za zavarivanje.
The term "about" in relation to a numerical value x means, for example, x±10%. 
Izraz "oko" u odnosu na brojnu vrijednost x znači, na pr. x610%.
In the present process, the optional removal or solubilisation of insoluble matter is preferably carried out prior to decolourisation. 
U sadašnjem postupku, opcionalno uklanjanje ili solubiliziranje netopljive tvari se poželjno izvodi prije obezbojenja.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) ciprodinil.
The tablet as claimed in claim 2, having the following composition: 
Tableta prema patentnom zahtjevu 2, koja u osnovi ima slijedeći sastav:
Y is an optionally substituted aryl or an optionally substituted heteroaryl which may be optionally substituted with 1-3 substituents independently selected from halo, C1-C4 alkyl, halogenated C1-C4 alkyl, or C1-C4 alkoxy; 
Y je opcijski supstituiran aril ili opcijski supstituiran heteroaril koji može biti opcijski supstituiran sa 1-3 supstituenta nezavisno odabrana od halo, Cy-C, alkila, halogeniranog C;-C, alkila, ili C,-C, alkoksi;
or a tautomer, enantiomer or salt thereof. The compound according to claim 2, having the formula IIb: 
Spoj u skladu s patentnim zahtjevom 2, naznačen time što je spoj s formulom Ila ili IIb:
Spheroids suitable for use in a pharmaceutical preparation comprising a matrix core comprising (1) as a spheronising aid, between 50 and 95% w/w of glyceryl monostearate, the percentage by weight being based on the weight of the entire core, (2) a polymeric binder selected from the group consisting of polyvinyl pyrrolidone, carboxypolymethylene, acrylic polymers, hydroxypropylmethyl cellulose, carboxymethyl cellulose, polyethylene oxide, polyethylene glycol, and poloxamer, (3) hydromorphone or a pharmaceutically acceptable salt thereof, and (4) optionally a coating surrounding the core, wherein the spheroids are obtained by extrusion and spheronisation, and the matrix core contains no or substantially no microcrystalline cellulose. 
Cc) sferonizacije ekstrudata; d) sušenja i prosijavanja rezultirajućih sferoida; 1 e) izborno oblaganja osušenih sferoida, pri čemu se postupak izvodi u komercijalnim razmjerima. Obloženi sferoidi pogodni za uporabu u farmaceutskom preparatu koji sadrži jezgru matriksa koje sadrži kao pomoćno sredstvo za sferonizaciju između 30 1 95% (tež./tež.) gliceril monostearata, pri čemu su % (tež./tež.) zasnovani na težini neobloženih sferoida, i polimerno vezivno sredstvo, i omotač koji okružuje jezgru matriksa, pri čemu jezgra matriksa ne sadrži ili značajno ne sadrži mikrokristalnu celulozu.
The pharmaceutical composition of claim 6, wherein the compound of formula IIB is the compound of formula IIBb or a pharmaceutically acceptable salt, solvate, and/or ester thereof. 
Farmaceutski sastav prema patentnom zahtjevu 5, gdje spoj formule IIB je spoj formule IIBb: [image] [image] ili njegova farmaceutski prihvatljivu sol, solvat i/ili ester.
Atomizing device according to claim 2, wherein the nozzle tip 1 connected with the air transition cone A are reversibly connected to the housing 3. 
Uređaj za atomiziranje prema zahtjevu 2, naznačen time da su vrh mlaznice (1) spojen s konusom za prijelaz zraka (A) povratno spojeni na kućište (3).
The cells were stained in duplicate with 100mcg/ml of the anti-Nogo-A humanised antibodies followed by a 1:100 dilution of the PE-labelled anti-human IgG secondary (Sigma, #P8047). 
Te slanice obojane su u duplikatu s 100 pg/imf fumaniziranih protutijela protiv Nogo-A, uz naknadni dodatak 1:100 razrijeđenog sekundarnog protujudskog IgG obiježenog s PE (Sigma, br. P5047).
A pharmaceutical composition comprising prilocaine HCl and glucose in a hyperbaric solution of water for injection, said composition exhibiting a shelf-life, at ambient temperature, of at least 5 years and whose 2-methylaniline content, throughout the entire shelf-life duration, is less than 0.10% relative to the quantity of prilocaine HCl contained, wherein the prilocaine HCl content is from 1.8% to 2.2% (wN), the glucose content, expressed as anhydrous glucose, is from 5.4% to 6.6% (w/V) and the osmolarity is in the range from 490 to 540 mOsm/kg. 
Farmaceutska kompozicija koja sadrži prilokain HCI i glukozu u hiperbaričnoj otopini vode za injekciju, naznačena time, što kompozicija ima rok trajanja, na temperaturi sredine, od najmanje 5 godina i čiji je sadržaj 2- metilanilina, tokom cjlokupnog roka trajanja, manji od 0.10% u odnosu na količinu sadržanog prilokaina HCI, gdje je sadržaj prilokaina HCI od 1.8% do 2.2% (tež./vol.), sadržaj glukoze, izražen kao anhidrirana glukoza, je od 5.4% do 6.6% (tež./vol.) i osmolaritet je u opsegu od 490 do 540 mOsmykg.
The methanesulphonate salt of Isomer B was prepared by dissolving a mixture of 1 equivalent of Isomer B from Example 3C and 1 equivalent of methane sulphonic acid in the minimum amount of ethanol and then adding diethyl ether. 
Metansulfonat sol Izomera B je pripremljena otapanjem smjese 1 ekvivalenta Izomera B iz Primjera 3C 1 1 ekvivalenta metan sulfonske kiseline u minimalnoj količini etanola i zatim dodavanjem dietil etera.
an indentation formed in the wall, weakening a part of the wall for allowing piercing by application of a predetermined force; 
- < zarezizrađen u stijenci, oslabljeni dio stijenke da se omogući probijanje djelovanjem prethodno određene sile;
The AAV vector of claim 8, wherein the gene encodes the SMN protein and the disorder is spinal muscular atrophy (SMA). 
AAV vektor iz patentnog zahtjeva 8, pri čemu gen kodira SMN protein 1 poremećaj je spinalna mišićna atrofija (SMA).
the polysaccharide chains are essentially free of chemically intact non-sulfated iduronic and/or glucuronic acids from pentasaccharide sequences mediating the anticoagulant effect of heparin and heparin sulfate; 
(vV) polisaharidni lanci su u osnovi bez kemijski intaktnih ne-sulfatnih iduronskih i/ili glukuronskih kiselina iz pentasaharidnih sekvenci koje posreduju u efektu antikoagulacije; i
to form a compound of formula (XX): wherein P1 is as defined above; 
5 da bi se formirao spoj formule (XX): t
a barrier apparatus (17) for preventing or hindering liquids and/or gases from passing over from the reactor (1) into the first reservoir unit (8). 
(k) uređaj za blokiranje (17) za sprječavanje ili onemogućavanje prolaska tekućina i/ili plinova iz reaktora (1) u prvu jedinicu spremnika (8).
Conductors 12, 14 are comprised in a leakage current detection circuit in the conductors 12, 14 themselves, in this case a differential current transformer 30, realized on a toroidal core with known techniques. 
Vodiči 12, 14 su uključeni u krug detekcije parazitne struje u samim vodičima 12,14; u tom slučaju diferencijalni strujni transformator 30, namotan na toroidnu jezgru na poznat način.
The method of claim 10, wherein the anion exchange chromatography is performed using a strong anion exchange resin having —N+(CH3)3 functional groups, or a resin having similar characteristics. 
Metda iz patentnog zahtjeva 10, pri čemu se anionska izmjenjivačka kromatografija provodi koristeći jaku amionsku izmjenjivačku smolu koja ima -N*(CH3)3 funkcijske grupe, ili smolu sličnih karakteristika.
The gene construction according to claim 2, wherein said gene construction is an expression vector. 
Genski konstrukt u skladu s patentnim zahtjevom 2, naznačen time što je navedeni genski konstrukt ekspresijski vektor.
The product was dried to give 2.49g of pure compound as a white solid. 
Produkt se osuši kako bi se dobilo 2,49 g čistog spoja u obliku bijele krutine.
A compound selected from the group consisting of: 5-[Acetyl-(3,5-bis-trifluoromethyl-benzyl)-amino[-7-trifluoromethyl-2,3,4,5-tetrahydrobenzo[b]azepine-1-carboxylic acid isopropyl ester, 
[image] [image] [image] Spoj u skladu s patentnim zahtjevom 1, kojeg se bira iz skupine koju čine:
In other preferred embodiments, the susceptibility diagnosis is based on the patient having a systemic autoimmune disease. 
Antagonist za uporabu u skladu sa zahtjevom 34, naznačen time, da je dijagnoza osjetljivosti zasnovana na tome da pacijent ima sistemsku autoimunu bolest.
The antibody or antibody fragment according to any one of claims 1 to 10 for use in a method for treating a disease or disorder, wherein the disease or disorder is improved, ameliorated or inhibited by removal, inhibition or reduction of human interleukin-4 (hIL-4) activity. 
Antitijelo ili fragment koji se vezuje za antigen za primjenu u metodi prema zahtjevu 7, naznačeno time, što se antitijelo ili njegov fragment koji se vezuje za antigen sastoji od varijabilne regije lakog lanca (LCVR) koja sadrži aminokiselinsku sekvencu SEQ ID NO:164.
The pharmaceutical composition of claim 1, wherein the micellar particle increases the production of anti-G protein antibodies in a host. 
Postupak sukladno patentnom zahtjevu 1, da je micela sposobna povećati proizvodnju antitijela protiv G proteina u domaćinu.
A is selected from the group consisting of phenyl, pyridyl, indolyl, thienyl, benzothienyl, indazolyl, benzisoxazolyl, benzofuranyl, benzotriazolyl, furanyl, benzothiazolyl, thiazolyl, each optionally substituted with one or two groups independently selected from the group consisting of OH, lower alkyl, lower cycloalkyl; 
A je izabran iz grupe koju čini fenil, piridil, indolil, tienil, benzotienil, indazolil, benzizoksazolil, benzofuranil, benzotriazolil, furanil, benzotiazolil, tiazolil, svaki izborno supstituiran sa jednom ili dvije grupe nezavisno izabran iz grupe koju čini OH, C,4 alkil i C34 cikloalkil;
The method of claim 1, wherein the amount of the compound of formula R1SR2 ranges from about 1.0 to about 9.0, from about 2.0 to about 5.0, or from about 2.5 to about 3.5 molar equivalents per molar equivalent of trichloroisocyanuric acid. 
Postupak prema zahtjevu 1, naznačen time da je količina spoja formule R;SR> u rasponu od oko 1.0 do oko 9.0, od oko 2.0 do oko 5.0 ili od oko 2.5 do oko 3.5 molarnih ekvivalenata po molarnom ekvivalentu reagensa koji sadrži klor.
Use according to claim 37 wherein the GPR119 agonist has an EC50 of less than 10 µM. 
Uporaba u skladu sa zahtjevom 37, naznačena time, da GPR119 agonist ima EC50 manji od 10 uM.